Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011


Outcome Predictors in Treatment of Yaws

Oriol MitjàComments to Author , Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique Bassat
Author affiliations: Author affiliations: Lihir Medical Centre, Lihir Island, Papua New Guinea (O. Mitjà, R. Hays, A. Ipai, D. Gubaila, F. Lelngei, M. Kirara, R. Paru); Barcelona Centre for International Health Research, Barcelona, Spain (Q. Bassat)

Main Article

Table 1

Demographic data, clinical signs/symptoms, laboratory results, and outcome after treatment of yaws in 138 case-patients, Papua New Guinea, January–September, 2009*

Characteristic Total no. (%) patients, N = 138
Mean age, y (SD) 9.6 (4.4)
Male sex
81 (58.7)
VDRL titer
16 54 (39.1)
32 33 (23.9)
64 42 (30.4)
9 (6.5)
Primary skin lesion 81 (58.7)
Secondary stage
63 (45.7)†
Family history
36 (26.1)
Treatment with IM penicillin G benzathine 138 (100.0)
Clinical healing 132 (95.7)
Concurrent disease 7 (5.1)‡
Seroconversion 63 (45.7)
Serologically defined treatment failure 24 (17.4)

*VDRL, Venereal Disease Research Laboratory; IM, intramuscular.
†Includes 7 cases of early yaws osteoperiostitis, among whom were 3 patients with dactylilitis.
‡Includes 3 cases of Plasmodium falciparum malaria, 1 case of P. vivax malaria, 1 case of acute diarrhea diagnosed at the 12-month follow-up visit, and 2 case-patients with a chronic underlying disease (1 case of congenital heart disease and 1 case of chronic asthma).

Main Article